Health
Emyria and partner Mind Medicine Australia launch psychedelic-assisted therapy program targeting PTSD – Proactive Investors Australia
EMDMA-001 has been modelled on a major Phase III clinical trial developed by the Multidisciplinary Association for Psychedelic Studies (MAPS).
EMDMA-001 has been modelled on a major Phase III clinical trial developed by the Multidisciplinary Association for Psychedelic Studies (MAPS). Emyria Ltd (ASX:EMD) and partner Mind Medicine Australia have launched the EMDMA-001 psychedelic-assisted therapy program targeting sufferers of treatment-resistant post-traumatic stress disorder (PTSD).
As a first step, and pending ethics approval, Emyria, an innovative drug development and clinical services company, will sponsor a major, independently monitored,…
-
Business16 hours agoCould a small investor today match the historic returns of Warren Buffett?
-
Business8 hours agoWhat’s Macquarie’s price target on Mineral Resources shares?
-
General15 hours agoPope Leo condemns wealthy living in a bubble of luxury
-
Noosa News14 hours agoQueensland government to set up $400m energy investment fund